logo

Gemphire Therapeutics Inc. (GEMP)



Trade GEMP now with
  Date
  Headline
3/15/2019 8:04:19 AM Gemphire Therapeutics Q4 Net Loss $3.7 Mln Or $0.26/Shr Vs Loss $6.7 Mln Or $0.63/Shr Last Year
1/3/2019 7:03:47 AM Arcturus Therapeutics Appoints Andrew Sassine As CFO
12/3/2018 8:11:41 AM Gemphire Therapeutics Conducts Review Of Range Of Strategic Alternatives
8/28/2018 7:01:39 AM Arcturus Therapeutics Names Andrew Sassine Interim CFO
8/13/2018 4:04:30 PM Gemphire Therapeutics Q2 Loss/share $0.47 Vs. Loss $0.99 Year Ago
8/10/2018 6:03:17 AM Gemphire Therapeutics Unveils Termination Of Phase 2a Trial Of Gemcabene In Pediatric NAFLD
5/3/2018 4:45:23 PM Gemphire Therapeutics Appoints Steven Gullans As Its President And CEO
2/8/2018 9:01:02 AM Gemphire Announces Pricing Of $22 Mln Public Offering Of Common Stock
1/17/2018 6:30:39 AM Gemphire Completes Patient Enrollment In INDIGO-1 Trial In Severe Hypertriglyceridemia Patients